Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common share equivalents):

	Years Ended December 31,
	2021		2020		2019
Class X preferred stock (if-converted to common stock)		—		—		587,445
Common stock warrants		13,760		13,904		13,904
Common stock options and restricted stock units		1,420,050		584,211		363,553
Employee stock purchase plan		2,045		1,602		1,958
Total		1,435,855		599,717		966,860

Summary of Net Loss Per Share

The following table summarizes our net loss per share (in thousands, except per share data):

	Years Ended December 31,
	2021			2020			2019
Numerator:
Net loss attributable to aTyr Pharma, Inc.	$	(33,768	)	$	(16,224	)	$	(23,603	)
Denominator:
Shares used in computing net loss per share, basic and diluted		19,080,878			9,160,269			3,355,600
Net loss per share - basic and diluted	$	(1.77	)	$	(1.77	)	$	(7.03	)